You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

SLYND Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Slynd patents expire, and when can generic versions of Slynd launch?

Slynd is a drug marketed by Exeltis Usa Inc and is included in one NDA. There are thirteen patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-five patent family members in twenty-nine countries.

The generic ingredient in SLYND is drospirenone. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the drospirenone profile page.

DrugPatentWatch® Generic Entry Outlook for Slynd

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 28, 2031. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (drospirenone), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Drug patent expirations by year for SLYND
Drug Prices for SLYND

See drug prices for SLYND

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SLYND
Generic Entry Date for SLYND*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for SLYND
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SLYND Tablets drospirenone 4 mg 211367 1 2022-01-07

US Patents and Regulatory Information for SLYND

SLYND is protected by thirteen US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of SLYND is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting SLYND

Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE

Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE

Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE

Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE

Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Exeltis Usa Inc SLYND drospirenone TABLET;ORAL 211367-001 May 23, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Exeltis Usa Inc SLYND drospirenone TABLET;ORAL 211367-001 May 23, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Exeltis Usa Inc SLYND drospirenone TABLET;ORAL 211367-001 May 23, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for SLYND

When does loss-of-exclusivity occur for SLYND?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 1670
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 11273605
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 2012033391
Estimated Expiration: ⤷  Try a Trial

Patent: 2019008317
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 03721
Estimated Expiration: ⤷  Try a Trial

Patent: 03062
Estimated Expiration: ⤷  Try a Trial

Patent: 61421
Estimated Expiration: ⤷  Try a Trial

Chile

Patent: 12003685
Estimated Expiration: ⤷  Try a Trial

Colombia

Patent: 40328
Estimated Expiration: ⤷  Try a Trial

Croatia

Patent: 0200155
Estimated Expiration: ⤷  Try a Trial

Patent: 0220332
Estimated Expiration: ⤷  Try a Trial

Cyprus

Patent: 22544
Estimated Expiration: ⤷  Try a Trial

Patent: 25061
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 88114
Estimated Expiration: ⤷  Try a Trial

Patent: 32448
Estimated Expiration: ⤷  Try a Trial

Ecuador

Patent: 12012359
Estimated Expiration: ⤷  Try a Trial

Patent: 15032906
Estimated Expiration: ⤷  Try a Trial

Patent: 15032911
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 8680
Estimated Expiration: ⤷  Try a Trial

Patent: 1291372
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 88114
Estimated Expiration: ⤷  Try a Trial

Patent: 32448
Estimated Expiration: ⤷  Try a Trial

Patent: 56186
Estimated Expiration: ⤷  Try a Trial

France

Patent: C1020
Estimated Expiration: ⤷  Try a Trial

Patent: C1031
Estimated Expiration: ⤷  Try a Trial

Guatemala

Patent: 1200336
Estimated Expiration: ⤷  Try a Trial

Patent: 1200336A
Estimated Expiration: ⤷  Try a Trial

Patent: 1200336B
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 47689
Estimated Expiration: ⤷  Try a Trial

Patent: 58176
Estimated Expiration: ⤷  Try a Trial

Patent: 000016
Estimated Expiration: ⤷  Try a Trial

Patent: 200018
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 10159
Estimated Expiration: ⤷  Try a Trial

Patent: 13529665
Estimated Expiration: ⤷  Try a Trial

Lithuania

Patent: 2021523
Estimated Expiration: ⤷  Try a Trial

Patent: 2022513
Estimated Expiration: ⤷  Try a Trial

Patent: 88114
Estimated Expiration: ⤷  Try a Trial

Patent: 32448
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 9952
Estimated Expiration: ⤷  Try a Trial

Patent: 4971
Estimated Expiration: ⤷  Try a Trial

Patent: 12014629
Estimated Expiration: ⤷  Try a Trial

Patent: 19004393
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 5176
Estimated Expiration: ⤷  Try a Trial

Norway

Patent: 20015
Estimated Expiration: ⤷  Try a Trial

Peru

Patent: 130780
Estimated Expiration: ⤷  Try a Trial

Patent: 161410
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 88114
Estimated Expiration: ⤷  Try a Trial

Patent: 32448
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 88114
Estimated Expiration: ⤷  Try a Trial

Patent: 32448
Estimated Expiration: ⤷  Try a Trial

Serbia

Patent: 826
Estimated Expiration: ⤷  Try a Trial

Patent: 027
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 88114
Estimated Expiration: ⤷  Try a Trial

Patent: 32448
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 1209743
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 2164693
Estimated Expiration: ⤷  Try a Trial

Patent: 2210982
Estimated Expiration: ⤷  Try a Trial

Patent: 2539030
Estimated Expiration: ⤷  Try a Trial

Patent: 130048227
Estimated Expiration: ⤷  Try a Trial

Patent: 170085604
Estimated Expiration: ⤷  Try a Trial

Patent: 190073598
Estimated Expiration: ⤷  Try a Trial

Patent: 210013663
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 77886
Estimated Expiration: ⤷  Try a Trial

Patent: 08657
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SLYND around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 4056186 COMPOSITION PHARMACEUTIQUE COMPRENANT DE LA DROSPIRÉNONE ET ENSEMBLE CONTRACEPTIF (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT) ⤷  Try a Trial
European Patent Office 2588114 COMPOSITION PHARMACEUTIQUE CONTENANT DE LA DROSPIRÉNONE ET KIT CONTRACEPTIF (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT) ⤷  Try a Trial
South Korea 20190073598 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트 (Pharmaceutical composition comprising drospirenone and contraceptive kit) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for SLYND

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3632448 C202230031 Spain ⤷  Try a Trial PRODUCT NAME: DROSPIRENONA; NATIONAL AUTHORISATION NUMBER: 84603-SE/H/1869/001/DC; DATE OF AUTHORISATION: 20191025; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): SE/H/1809/001/DC; DATE OF FIRST AUTHORISATION IN EEA: 20191016
2588114 2020C/518 Belgium ⤷  Try a Trial PRODUCT NAME: DROSPIRENON; AUTHORISATION NUMBER AND DATE: BE548284 20191107
3632448 22C1031 France ⤷  Try a Trial PRODUCT NAME: DROSPIRENONE; NAT. REGISTRATION NO/DATE: NL49691 20191121; FIRST REGISTRATION: DK - 31332 20191016
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.